Effector Therapeutics Inc

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company that develops selective translation regulator inhibitors for cancer treatment. Its lead candidate, Zotatifin, is an eIF4A inhibitor in Phase 1/2 trials for solid tumors and has completed a Phase 2 trial in combination with fulvestrant and abemaciclib for ER+ breast cancer. The company also develops Tomivosertib, an oral small-molecule MNK inhibitor in Phase 2b trials for metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules targeting eIF4E. Founded in 2012, eFFECTOR Therapeutics is headquartered in Solana Beach, California.